The impact of reducing dose frequency on health outcomes

Clinical Therapeutics

Volumn 25, Issue 8, 2003, Pages 2307-2335

  Richter, Anke ^a   Anton, Susan F ^b   Koch, Peter ^b   Dennett, Susan L ^a  

^a RTI HEALTH SOLUTIONS   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Dose frequency; Drug costs; Patient adherence; Quality of life

Indexed keywords

ANTIANGINA PECTORIS AGENT; ANTIASTHMATIC AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CARBIDOPA; EPROSARTAN; ETODOLAC; FELODIPINE; FLUTAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIPIZIDE; GLIQUIDONE; INDINAVIR; ISRADIPINE; LANSOPRAZOLE; LEVODOPA; LOSARTAN; METHYLPHENIDATE; MOMETASONE FUROATE; MORPHINE; PHENYTOIN; QUINIDINE; THEOPHYLLINE; TIAGABINE; UNINDEXED DRUG; ZIDOVUDINE; ZILEUTON;

BIBLIOGRAPHIC DATABASE; BUDGET; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; COST CONTROL; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG PREFERENCE; DRUG SAFETY; HEALTH CARE UTILIZATION; HUMAN; MEDICAL LITERATURE; MEDLINE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PATIENT SATISFACTION; QUALITY OF LIFE; REVIEW;

EID: 0041384468     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(03)80222-9     Document Type: Review

References (130)

1. Wang W, Husan F, Chow SC. The impact of patient compliance on drug concentration profile in multiple doses. Stat Med. 1996;15:659-669.
2. Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984;100:258-268.
3. O'Brien MK, Petrie K, Raeburn J. Adherence to medication regimens: Updating a complex medical issue. Med Care Rev. 1992;49:435-454.
4. Cramer JA. Effect of partial compliance on cardiovascular medication effectiveness. Heart. 2002;88:203-206.
5. Cramer JA. Enhancing patient compliance in the elderly. Role of packaging aids and monitoring. Drugs Aging. 1998;12:7-15.
6. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20:1512-1517.
7. Davidsson GK, Edwards JS, Davidson C. Comparison of once daily and twice daily nisoldipine as monotherapy in essential hypertension. Control Clin Trials. 1996;17:117-122.
8. Gregoire JP, Moisan J, Guibert R, et al. Determinants of discontinuation of new courses of antihypertensive medications. J Clin Epidemiol. 2002;55:728-735.
9. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther. 2001;23:1296-1310.
10. Iskedjian M, Einarson TR, MacKeigan LD, et al. Relationship between daily dose frequency and adherence to antihypertensive pharmacotherapy: Evidence from a meta-analysis. Clin Ther. 2002;23:302-316.
11. Dezii CM, Kawabata H, Tran M. Effects of once-daily and twice-daily dosing on adherence with prescribed glipizide oral therapy for type 2 diabetes. South Med J. 2002;95:68-71.
12. Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy Clin Ther. 1998;20:671-681.
13. Christensen HR, Kampmann JP, Simonsen K. A randomized comparison of isradipine slow release given once daily with isradipine twice daily on 24 hour blood pressure in hypertensive patients. J Hum Hypertens. 1991;5:121-127.
14. Morgan T, Morgan O, Anderson A. A study of the efficacy of felodipine given once or twice daily in the management of elderly hypertensive patients. J Hum Hypertens. 1996;10:193-197.
15. Hedner T, Himmelmann A, for the Eprosartan Multinational Study Group. The efficacy and tolerance of one to two daily doses of eprosartan in essential hypertension. J Hypertens. 1999;17:129-136.
16. Wahlin-Boll E, Groop L, Karhumaa S, et al. Therapeutic equivalence of once- and thrice-daily glipizide. Eur J Clin Pharmacol. 1986;31:95-99.
17. Wan Mohamad WB, Tun Fizi A, Ismail RB, Mafauzy M. Efficacy and safety of single versus multiple daily doses of glibenclamide in type 2 diabetes mellitus. Diabetes Res Clin Pract. 2000;49:93-99.
18. Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. PharmacoEconomics. 1994;5:482-504.
19. Shepp DH, Ramirez-Ronda C, Dall L, et al. A comparative trial of zidovudine administered every four versus every twelve hours for the treatment of advanced HIV disease. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:283-288.
20. James JS. Crixivan (Indinavir): Three doses daily, not two, in most regimens. AIDS Treat News. 1998;304:4-5.
21. Carlson AM, Morris LS, Perfetto EM, et al. Quality of sleep in patients with osteo-arthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998;38:31-36.
22. Rickels K, Smith WT, Glaudin V, et al. Comparison of two dosage regimens of fluoxetine in major depression. J Clin Psychiatry. 1985;46:38-41.
23. Buchanan RA, Kinkel AW, Goulet JR, Smith TC. The metabolism of diphenylhydantoin (Dilantin) following once-daily administration. Neurology. 1972;22:126-130.
24. Sachdeo RC, Leroy RF, Krauss GL, et al. Tiagabine therapy for complex partial seizures. A dose-frequency study. The Tiagabine Study Group. Arch Neurol. 1997;54:595-601.
25. Biraben A, Beaussart M, Josien E, et al. Comparison of twice- and three times daily tiagabine for the adjunctive treatment of partial seizures in refractory patients with epilepsy: An open label, randomised, parallel-group study. Epileptic Disord. 2001;3:91-100.
26. Baldi F, Morselli-Labate AM, Cappiello R, Ghersi S. Daily low-dose versus alternate day full-dose lansoprazole in the maintenance treatment of reflux esophagitis. Am J Gastroenterol. 2002;97:1357-1364.
27. Thrasher JB, Deeths J, Bennett C, et al. Comparative study of the clinical efficacy of two dosing regimens of flutamide. Mol Urol. 2000;4:259-263.
28. Toogood JH, Baskerville JC, Jennings B, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol. 1982;70:288-298.
29. Nyholm E, Frame MH, Cayton RM. Therapeutic advantages of twice-daily over four-times daily inhalation budesonide in the treatment of chronic asthma. Eur J Respir Dis. 1984;65:339-345.
30. Boyd G, Abdallah S, Clark R. Twice or four times daily beclomethasone dipropionate in mild stable asthma? Clin Allergy. 1985;15:383-389.
31. Malo JL, Cartier A, Merland N, et al. Four-times-a-day dosing frequency is better than a twice-a-day regimen in subjects requiring a high-dose inhaled steroid, budesonide, to control moderate to severe asthma. Am Rev Respir Dis. 1989;140:624-628.
32. Gagnon M, Cote J, Milot J, et al. Comparative safety and efficacy of single or twice daily administration of inhaled beclomethasone in moderate asthma. Chest. 1994;105:1732-1737.
33. Munch EP, Laursen LC, Dirksen A, et al. Dose frequency in the treatment of asthmatics with inhaled topical steroids. Comparison between a twice daily and a once daily dosing regimen. Eur J Respir Dis. 1985;67:254-260.
34. Malo JL, Cartier A, Ghezzo H, et al. Comparison of four-times-a-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir Med. 1995;89:537-543.
35. DuBuske LM, Grossman J, Dube LM, et al, for the Zileuton Study Group. Randomized trial of zileuton in patients with moderate asthma: Effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Am J Manag Care. 1997;3:633-640.
36. Kemp JP, Berkowitz RB, Miller SD, et al. Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2000;106:485-492.
37. Nayak AS, Banov C, Corren J, et al. Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma. Ann Allergy Asthma Immunol. 2000;84:417-424.
38. Noonan M, Karpel JP, Bensch GW, et al. Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler. Ann Allergy Asthma Immunol. 2001;86:36-43.
39. Pahwa R, Busenbark K, Huber SJ, et al. Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology. 1993;43:677-681.
40. Aarli JA, Gilhus NE. Sinemet CR in the treatment of patients with Parkinson's disease already on long-term treatment with levodopa. Neurology. 1989;39(11 Suppl 2): 82-85.
41. Bulling MT, Wing LM, Burns RJ. Controlled release levodopa/carbidopa (Sinemet CR4) in Parkinson's disease - an open evaluation of efficacy and safety. Aust N Z J Med. 1991;21:397-400.
42. Block G, Liss C, Reines S, et al. Comparison of immediate-release and controlled-release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR FIRST Study Group. Eur Neurol. 1997;37:23-27.
43. Morganroth J, Hunter H. Comparative efficacy and safety of short-acting and sustained release quinidine in the treatment of patients with ventricular arrhythmias. Am Heart J. 1985;110:1176-1181.
44. O'Brien T, Mortimer PG, McDonald CJ, Miller AJ. A randomized crossover study comparing the efficacy and tolerability of a novel once-daily morphine preparation (MXL capsules) with MST Continus tablets in cancer patients with severe pain. Pall Med. 1997;11:475-482.
45. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics. 2001;107:E105.
46. Welch MJ, Kemp JP Ostrom NK, et al. A comparative study of a new once-a-day theophylline preparation with Theo-Dur given twice daily. J Asthma. 1993;30:211-218.
47. Berkowitz RB, Tinkelman DG, Marcoux JP, et al. Conversion from twice- to once-daily extended-release theophylline treatment in patients with reversible airway obstruction. J Asthma. 1995;32:275-284.
48. Ferrari M, Oliveri M, Lampronti G, et al. Effect of once daily and twice daily sustained release theophylline formulations on daytime variation of bronchial hyper-responsiveness in asthmatic patients. Thorax. 1997;52:969-974.
49. Birkeland KI, Furuseth K, Melander A, et al. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months. Diabetes Care. 1994;17:45-49.
50. Harrower AD. Comparison of efficacy, secondary failure rate, and complications of sulfonylureas. J Diabetes Complications. 1994;8:201-203.
51. Roca-Cusachs A, Oigman W, Lepe L, et al. A randomized, double-blind comparison of the antihypertensive efficacy and safety of once-daily losartan compared to twice-daily captopril in mild to moderate essential hypertension. Acta Cardiol. 1997;52:495-506.
52. Leenen FH, Wilson TW, Bolli P, et al. Patterns of compliance with once versus twice daily antihypertensive drug therapy in primary care: A randomized clinical trial using electronic monitoring. Can J Cardiol. 1997;13:914-920.
53. van Noord JA, Bantje TA, Eland ME, et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. The Dutch Tiotropium Study Group. Thorax. 2000;55:289-294.
54. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1-yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216.
55. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965.
56. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest. 2002;122:47-55.
57. Miner CM, Brown EB, Gonzales JS, Munir R. Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. J Clin Psychiatry. 2002;63:232-240.
58. Olowoyeye JO, Thadani U, Parker JO. Slow release oxprenolol in angina pectoris: Study comparing oxprenolol, once daily, with propranolol, four times daily. Am J Cardiol. 1981;47:1123-1127.
59. Lin WR, Lin HH, Lee SS, et al. Comparative study of the efficacy and safety of valacyclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect. 2001;34:138-142.
60. Kesten S, Chapman KR, Broder I, et al. A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma. Am Rev Respir Dis. 1991;144:622-625.
61. Ekstrom T, Ringdal N, Sobradillo V, et al. Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respir Med. 1998;92:1040-1045.
62. Zahner B, Stefan H, Blankenhorn V, et al. Once-daily versus twice-daily vigabatrin: Is there a difference? The results of a double-blind pilot study. Epilepsia. 1999;40:311-315.
63. D'Alonzo GE, Smolensky MH, Feldman S, et al. Twenty-four hour lung function in adult patients with asthma. Chronoptimized theophylline therapy once-daily dosing in the evening versus conventional twice-daily dosing. Am Rev Respir Dis. 1990;142:84-90.
64. Grandas F, Martinez-Martin P, Linazasoro G, for the STAR Multicenter Study Group. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: The STAR Study. J Neurol. 1998;245(Suppl 1):S31-S33.
65. Mohiuddin SM, Hilleman DE. Substituting nifedipine-GITS for immediate-release calcium-channel antagonists in patients with stable angina pectoris. Curr Ther Res Clin Exp. 1991;50:546-552.
66. Niemeyer MG, Kleinjans HA, de Ree R, et al, for the Dutch Mononitrate Quality of Life (DUMQOL) Study Group. Comparison of multiple-dose and once-daily nitrate therapy in 1212 patients with stable angina pectoris: Effects on quality of life indices. Angiology. 1997;48:855-862.
67. Welsh PW, Reed CE, Conrad E. Timing of once-a-day theophylline dose to match peak blood level with diurnal variation in severity of asthma. Am J Med. 1986;80:1098-1102.
68. Davis R, McTavish D. Budesonide. An appraisal of the basis of its pharmacoeco-nomic and quality-of-life benefits in asthma. PharmacoEconomics. 1995;7:457-470.
69. Balon R, Arfken CL, Mufti R. Patients' preferences about medication dosing regimens. Psychiatr Serv. 1998;49:1095.
70. Wong W, Wilson Norton J, Wittkowsky AK. Influence of warfarin regimen type on clinical and monitoring outcomes in stable patients in an anticoagulation management service. Pharmacotherapy. 1999;19:1385-1391.
71. Crespo-Fierro M. Compliance/adherence and care management in HIV disease. J Assoc Nurses AIDS Care. 1997;8:43-54.
72. Bass D, Smith M. HIV patients prefer once-daily regimens. Abstract presented at: XIV International AIDS Conference; July 7-12, 2002; Barcelona, Spain. Abstract MoPeB3290.
73. Balsbaugh TA, Chambers CV, Diamond JJ. Asthma controller medications: What do patients want? J Asthma. 1999;36:591-596.
74. Lawrence JD, Lawrence DB, Carson DS. Optimizing ADHD therapy with sustained-release methylphenidate. Am Fam Physician. 1997;55:1705-1709
75. Fischer RG. Compliance-oriented prescribing: Simplifying drug regimens. J Fam Pract. 1980;10:427-435.
76. Vogel S, Grady C, Ropka M. Factors affecting investigational medication compliance in healthy HIV-infected participants of randomized control trial (RCT) comparing AZT and interferon-alpha (IFN-alpha). Int Conf AIDS. 1993;9:559. Abstract POB44-2544.
77. Skaer TL, Sclar DA, Robison LM, et al. Effect of pharmaceutical formulation for diltiazem on health care expenditures for hypertension. Clin Ther. 1993;15:905-911.
78. Levenson T, Grammer LC, Yarnold PR, Patterson R. Cost-effective management of malignant potentially fatal asthma. Allergy Asthma Proc. 1997;18:73-78.
79. Hempel AG, Wagner ML, Maaty MA, Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother. 1998;32:878-883.
80. Jordan TJ, Reichman LB. Once-daily versus twice-daily dosing of theophylline. A decision analysis approach to evaluating theophylline blood levels and compliance. Am Rev Respir Dis. 1989;140:1573-1577.
81. Schueler K. Cost-effectiveness issues in hypertension control. Can J Public Health. 1994;85(Suppl 2):S54-S56.
82. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841-845.
83. Grob PR. Antibiotic prescribing practices and patient compliance in the community Scand J Infect Dis Suppl. 1992;83:7-14.
84. Cockburn J, Reid AL, Bowman JA, Sanson-Fisher RW. Effects of intervention on antibiotic compliance in patients in general practice. Med J Aust. 1987;147:324-328.
85. Farmer KC, Jacobs EW, Phillips CR. Long-term patient compliance with prescribed regimens of calcium channel blockers. Clin Ther. 1994;16:316-326.
86. Andrejak M, Genes N, Vaur L, et al. Electronic pill-boxes in the evaluation of anti-hypertensive treatment compliance: Comparison of once daily versus twice daily regimen. Am J Hypertens. 2000;13:184-190.
87. Cramer JA, Mattson RH, Prevey ML, et al. How often is medication taken as prescribed? A novel assessment technique. JAMA. 1989;261:3273-3277.
88. Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(Suppl 1):18-22.
89. Eisen SA, Miller DK, Woodward RS, et al. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med. 1990;150:1881-1884.
90. Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30(Suppl 2):S171-S176.
91. Steenhoek A, Palmen FM. Sustained-release theophylline preparations. A comparative survey of 467 patients. Respiration. 1984;45:1-15.
92. Waeber B, Erne P, Saxenhofer H, Heynen G. Use of drugs with more than a twenty-four-hour duration of action. J Hypertens Suppl. 1994;12(Suppl 8):S67-S71.
93. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients' compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994;154:1349-1352.
94. Ayd FJ Jr. Rational pharmacotherapy: Once-a-day drug dosage. Dis Nerv Syst. 1973;34:371-378.
95. Cramer JA, Glassman M, Rienzi V. The relationship between poor medication compliance and seizures. Epilepsy Behav. 2002;3:338-342.
96. Cramer JA, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia. 1995;36:1111-1117.
97. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med. 2002;17:756-765.
98. Gifford RW Jr. Managing hypertension: The postgraduate medicine lecture. Postgrad Med. 1977;61:153-163.
99. Sutherland K. Nonadherence poses the biggest barrier to effective asthma treatment. Aust J Pharm. 1996;77:791-792.
100. Murphy J, Coster G. Issues in patient compliance. Drugs. 1997;54:797-800.
101. Urquhart J. Pharmacoeconomic consequences of variable patient compliance with prescribed drug regimens. PharmacoEconomics. 1999;15:217-228.
102. Bender B, Milgrom H, Rand C. Nonadherence in asthmatic patients: Is there a solution to the problem? Ann Allergy Asthma Immunol. 1997;79:177-186.
103. Goebel FD. Combination therapy from a clinician's perspective. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10(Suppl 1):S62-S68.
104. Freeman RC, Rodriguez GM, French JF. Compliance with AZT treatment regimen of HIV-seropositive injection drug users: A neglected issue. AIDS Educ Prev. 1996;8:58-71.
105. Ickovics JR, Meisler AW. Adherence in AIDS clinical trials: A framework for clinical research and clinical care. J Clin Epidemiol. 1997;50:385-391.
106. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA. 1997;277:145-153.
107. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
108. Schapiro JM, Winters MA, Vierra M, et al. Causes of long term efficacy and/or drug failure in protease (PR) inhibitor monotherapy. Int Conf AIDS. 1996;11:25. Abstract.
109. Nissen J. A case study in specialty pharmaceutical care. Stadtlander's Managed Pharmacy Serv. 1996;6:3-7.
110. Blaschke TF. Noncompliance and resistance to protease inhibitors. Abstract presented at: 4th Conference on Retroviral and Opportunistic Infections 1997; January 22-26, 1997; Washington, DC. Abstract S43:221.
111. Eljaschewitsch J, Bergmann F, Gruenewald T, Ruf B. Monitoring of compliance in HIV-positive patients treated with fansidar for primary (PP) and secondary (SP) prophylaxis of toxoplasmic encephalitis (TE) using serum level determination. Int Conf AIDS. 1992;8:B236.
112. Van Delden C, Gabriel V, Sudre P, et al, for the Swiss HIV Cohort Study Reasons for failure of prevention of Toxoplasma encephalitis. AIDS. 1996;10:509-513.
113. Alwood K, Keruly J, Moore-Rice K, et al. Effectiveness of supervised, intermittent therapy for tuberculosis in HIV-infected patients. AIDS. 1994;8:1103-1108.
114. Anastasio CJ. HIV and tuberculosis: Noncompliance revisited. J Assoc Nurses AIDS Care. 1995;6:11-23.
115. Ward-Able C, Phillips P, Tsoukas CM. The use of oral ganciclovir in the treatment of cytomegalovirus retinitis in patients with AIDS. CMAJ. 1996;154:363-368.
116. Klaus BD, Grodesky MJ. Assessing and enhancing compliance with antiretroviral therapy. Nurse Pract. 1997;22:211-212, 215, 219.
117. Smith M. The cost of noncompliance and the capacity of improved adherence to reduce health care expenditures. Improving Medication Adherence: Proceedings of a Symposium. Reston, Va: National Pharmaceutical Council; 1985:35-42.
118. National Pharmaceutical Council. Noncompliance with Medication Regimens: An Economic Tragedy. Reston, Va: National Pharmaceutical Council; 1994:2:1-12.
119. Strandberg LR. Drugs as a reason for nursing home admissions. J Am Health Care Assoc. 1984;10:20-23.
120. Hallas J, Davidsen O, Grodum E, et al. Drug-related illness as a cause of admission to a department of respiratory medicine. Respiration. 1992;59:30-34.
121. Jones JK, Gorkin L, Lian JF, et al. Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: A study of a United Kingdom population. BMJ. 1995;311:293-295.
122. Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: The importance of actual practice data. CMAJ. 1999;160:41-46.
123. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31-37.
124. Weir MR. The rationale for combination versus single-entity therapy in hypertension. Am J Hypertens. 1998;11:163S-169S.
125. Shenfield GM. Fixed combination drug therapy. Drugs. 1982;23:462-480.
126. Sverrisson T, Gross R, Pearson J, et al. The dorzolamide/timolol combination versus timolol plus pilocarpine: Patient preference and impact on daily life. United States Patient Preference Study Group. International Patient Preference Study Group. J Glaucoma. 1999;8:315-324.
127. Meichenbaum D, Turk DC. Treatment adherence: Terminology, incidence, and conceptualization. In: Facilitating Treatment Adherence: A Practitioner's Guidebook. New York: Plenum Press; 1987:19-40.
128. Dolce JJ, Crisp C, Manzella B, et al. Medication adherence patterns in chronic obstructive pulmonary disease. Chest. 1991;99:837-841.
129. Goughnour BR. Cost considerations of analgesic therapy: An analysis of the effects of dosing frequency and route of administration. Postgrad Med J. 1991;67(Suppl 2): S87-S91.
130. Sweetman L, Howard D, O'Neill D. Once-daily medications for older patients in the general hospital. J Am Geriatr Soc. 1999;47:629.